Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:
Schedule
Product: | Levothyroxine |
Active Ingredient: | Levothyroxine sodium 0.05mg |
Dosage Form: | Tablet |
New Zealand Sponsor: | Boucher & Muir (NZ) Limited t/a Mercury Pharma (NZ) |
Manufacturer: | Custom Pharmaceuticals Limited (UK), Hove, United Kingdom |
Note: This consent is given subject to the following conditions:
|
|
Note: This renewed consent is valid for two years from 11 November 2020. | |
Product: | Levothyroxine |
Active Ingredient: | Levothyroxine sodium 0.1mg |
Dosage Form: | Tablet |
New Zealand Sponsor: | Boucher & Muir (NZ) Limited t/a Mercury Pharma (NZ) |
Manufacturer: | Custom Pharmaceuticals Limited (UK), Hove, United Kingdom |
Note: This consent is given subject to the following conditions:
|
|
Note: This renewed consent is valid for two years from 11 November 2020. |
Dated this 5th day of November 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).